Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Axitinib in RCC with IVC Tumor Thrombus
NCT05969496Phase 2Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Dec 2023
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, axitinib in renal cell carcinoma (RCC), sponsored by University of Colorado Denver. Started Dec 2023; status: recruiting.
02
Drugs
pembrolizumabaxitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05969496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05969496.